Tissue Regenix Group PLC Hardman Research: CellRight transforming US growth

TIDMTRX

Tissue Regenix Group PLC

10 August 2017

Hardman Research: CellRight transforming US growth

CellRight Technologies: Transforming US growth prospects - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since launch of DermaPure, the focus has been on increasing penetration of the US woundcare market to access both in- and out-patient populations, via GPOs and Medicare, respectively. To accelerate growth in the US, TRX has announced the acquisition of CellRight Technologies, which has a synergistic regenerative technology based on bone. To fund the acquisition and provide more working capital, the company has raised GBP40m (gross) of new capital.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/10.08.17-cellright-transforming-us-growth-prospects.pdf

 
 To contact us:          Contacts:       mh@hardmanandco.com 
  Hardman & Co            Dr Martin       dmh@hardmanandco.com 
  35 New Broad Street     Hall            gp@hardmanandco.com 
  London                  Dr Dorothea 
  EC2M 1NH                Hill 
  www.hardmanandco.com    Dr Gregoire 
  Follow us on Twitter    Pave 
  @HardmanandCo 
 
                          +44 20 7194 
                          7622

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPMMTTMBMBBJR

(END) Dow Jones Newswires

August 10, 2017 08:10 ET (12:10 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024